Lumpi-ProVac Ind (Lympy Skin Disease Vaccine)
Technology Details:
• Lumpy skin disease (LSD), reported first time in India from Odisha state in
2019, has spread all across the country. The current outbreaks of the disease are
occurring with high morbidity and mortality in the cattle population of the
country.
• The emerging evidences suggest that the LSD virus (LSDV) can also cause mild
infection in buffaloes, horses and camel. :
• The disease in cattle is characterized by development of skin nodules which is
associated with fever, enlargement of lymph nodes and depression, eventually
resulting in reduced milk yield, abortion in pregnant animals and sterility in bulls. :
• Presently, homologous LSD vaccine is not available in the country. The
Government of India also authorized the use of goat pox vaccine to control LSD in
cattle. However, heterologous vaccine provides partial protection and is not as
efficacious as homologous vaccine.:
• ICAR-National Research Centre on Equines (ICAR-NRCE), Hisar (Haryana)
developed a homologous live-attenuated LSD vaccine, named Lumpi-ProVacInd
. :
Lumpi-ProVacInd is safe in animals and induces LSDV-specific antibody- and cellmediated immune response, besides providing a complete protection against
lethal LSDV challenge.:
• The virus used for developing Lumpi-ProVacInd was isolated at ICAR-NRCE Hisar
from skin scab collected from a naturally LSDV infected cattle at Ranchi
(Jharkhand) in 2019 (LSDV/2019/India/Ranchi). The virus was attenuated in Vero
cells and the 50th passage of the virus was used to prepare the vaccine.:
• Lumpi-ProVacInd is used for the prophylactic immunization of animals against
Lumpy Skin Disease. The immunity induced by homologous live-attenuated LSD
vaccines usually persists for a minimum period of 1 year.:
• A single dose of the vaccine contains 103.5 TCID50 of live-attenuated LSDV (Ranchi
strain). :
• The vaccine is stored at 4°C. The vaccine must be shipped on ice and must be used
within few hours after reconstitution.